Policy
Older, frail patients are still being let down by the regulators
Hans Wildiers is frustrated. “This drug is well-tolerated in older persons – this is a very frequent conclusion in publications. And it is often not a correct conclusion,” says the immediate past president of SIOG, the International Society of Geriatric…
Not too little, not too much… a lesson for cancer prevention from ancient civilisations
“If we could give every individual the right amount of nourishment and exercise, not too little and not too much, we would have found the safest way to health.” This quotation from Hippocrates pops up regularly in writings advocating a…
Beating cancer is complex – our messaging must be clear
A window of opportunity is opening up across Europe to reverse the ever-rising trend of new cancers and improve outcomes for patients everywhere. It’s been brought about in part by a major shift in favour of Europe taking on a…
Croatia’s cancer plan showcases the value of European cancer collaboration
Croatia has caught up with the rest of the EU in adopting a national cancer control plan. Sophie Fessl looks at how using EU guidance drawn from experiences of other member states helped them ensure it is relevant, patient-centred, and…
A silver lining: Could changes forced by the pandemic point to better ways to conduct our clinical trials?
Pragmatic adjustments to trial protocols were seen to be essential during the Covid-19 pandemic to avoid trials being abandoned or delayed. Most changes involved reducing the requirements for travelling to centralised trials centres and reducing the level of reporting requirements.…
Could covid-19 boost interest in drug repurposing in oncology?
Could the frantic search for drugs to treat patients severely affected by the covid-19 virus be a shot in the arm for new cancer treatments? There have been many headlines about repurposed agents, such as the highly debated antimalarial drug…
On a mission to beat cancer
One small step for man, one giant leap for mankind – the words Neil Armstrong pronounced as he completed humankind’s first mission to the moon, will – if the European Commission gets its way – soon be pronounced for other…
How retractions are helping cancer research
In 2015, cancer researcher Anil Potti - back then associated with Duke University in Durham, North Carolina - was found guilty of research misconduct by a US federal investigation led by the office for research integrity of the Department of…